Get the Stockscreener App
25.82
1.39%
-0.335
Dyne Therapeutics Inc stock is traded at $25.82, with a volume of 409.51K.
It is down -1.39% in the last 24 hours and up +8.62% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$26.15
Open:
$25.875
24h Volume:
409.51K
Relative Volume:
0.19
Market Cap:
$4.82B
Revenue:
-
Net Income/Loss:
$-451.71M
P/E Ratio:
-8.0019
EPS:
-3.2261
Net Cash Flow:
$-462.19M
1W Performance:
-3.46%
1M Performance:
+8.62%
6M Performance:
+67.66%
1Y Performance:
+109.14%
1-Day Range:
$25.46
$26.31
1-Week Range:
$25.30
$27.30
52-Week Range:
$11.64
$27.30
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
25.79 | 4.80B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
529.87 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.70 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.30 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.62 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
368.07 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $54,012,900.00 in Stock - MarketBeat
Dyne Therapeutics CCO Executes Automatic Sale of 226 Shares to Cover RSU Tax Withholding - Kalkine Media
Dyne Therapeutics CEO John Cox Sells 4,986 Shares to Cover Tax Withholding on RSUs - Kalkine Media
Dyne therapeutics director Jason Rhodes sells $65.2m of common stock - Investing.com
Dyne Therapeutics (DYN) director's preset stock sale via Atlas funds - Stock Titan
Dyne Therapeutics (DYN) CFO sells shares in tax withholding trade - Stock Titan
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock By Investing.com - Investing.com UK
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock - Investing.com
Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CMO has shares sold for tax withholding - Stock Titan
Dyne Therapeutics (DYN) CEO's tax-driven sale to cover RSU taxes - Stock Titan
Wainwright reiterates Dyne Therapeutics stock rating on trial outlook By Investing.com - Investing.com Canada
Bank of America Corp DE Has $26.17 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Dyne Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
DYN Company (Nasdaq: DYN) holder plans 4,986-share sale worth $131,034 - Stock Titan
DYN (DYN) insider notice details planned share sale and prior trades - Stock Titan
DYN (DYN) shareholder Doug Kerr plans sale of 2,443 common shares - Stock Titan
Dyne Therapeutics (DYN): Atlas Venture funds report 3.6% beneficial stake in 13G/A - Stock Titan
Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson - Stock Titan
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Dyne Therapeutics stock hits 52-week high at 27.19 USD By Investing.com - Investing.com Nigeria
Dyne Therapeutics stock hits 52-week high at 27.19 USD - Investing.com
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - rttnews.com
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial - webull.com
FMR LLC Expands Dyne Therapeutics Stake: A Strategic Bet on Neur - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week HighHere's What Happened - MarketBeat
Discipline and Rules-Based Execution in DYN Response - Stock Traders Daily
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus - Sahm
Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Inc (DYN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dyne Therapeutics, Inc. Revenue Breakdown – NASDAQ:DYN - TradingView
FMR LLC (DYN) discloses 6.8% Dyne Therapeutics stake in amended ownership filing - stocktitan.net
Dyne Therapeutics stock hits 52-week high at 26.8 USD By Investing.com - Investing.com UK
Dyne Therapeutics stock hits 52-week high at 26.8 USD - Investing.com
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week HighShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 56% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Weekly Recap: BLA accepted for Z‑Rostudirsen and RBC raises PT to $35 - tradingview.com
Dyne Therapeutics, Inc. $DYN Shares Purchased by Renaissance Technologies LLC - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Purchased by Perceptive Advisors LLC - MarketBeat
DYNE THERAPEUTICS, INC : RBC RAISES TARGET PRICE TO $35 FROM $30 - webull.com
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $44 to $47 - Moomoo
Dyne Therapeutics, Inc. $DYN Shares Sold by Vivo Capital LLC - MarketBeat
Janus Henderson Group PLC Sells 240,346 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
RBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative Risk - marketscreener.com
Stempoint Capital LP Sells 329,125 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
DYN SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rhodes Jason P | Director |
Aug 13 '26 |
Sale |
26.20 |
426,412 |
11,171,994 |
751,411 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Aug 13 '26 |
Sale |
26.28 |
226 |
5,939 |
153,982 |
| Kerr Douglas | Chief Medical Officer |
Aug 13 '26 |
Sale |
26.28 |
1,556 |
40,892 |
167,599 |
| Cox John | CEO & President |
Aug 13 '26 |
Sale |
26.28 |
4,986 |
131,032 |
363,165 |
| Lucera Erick | Chief Financial Officer |
Aug 13 '26 |
Sale |
26.28 |
1,797 |
47,225 |
119,766 |
1.14%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):